{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:06:53Z","timestamp":1784567213377,"version":"3.55.0"},"reference-count":142,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The treatment landscape for relapsed or refractory multiple myeloma (RRMM) has evolved significantly with the introduction of T cell\u2013redirecting therapies. This review details key pharmacology, clinical efficacy, and safety information for bispecific antibodies (bsAbs) approved or under investigation for RRMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Multiple myeloma eventually relapses in nearly all patients, necessitating the continuous development of novel therapeutics. The 3 main targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor homolog 5 (FcRH5). Clinical trials have demonstrated robust single-agent efficacy in patient populations with difficult-to-treat RRMM, including in patients with penta-refractory disease. However, these therapies are associated with unique toxicities, including cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome, as well as significant infection risks. Risk can be reduced through close monitoring, optimized premedication regimens, and step-up dosing strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The remarkable efficacy of bsAbs in RRMM combined with a maturing understanding of their toxicity profiles is fundamentally reshaping the RRMM treatment landscape.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag203","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:16:51Z","timestamp":1783696611000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapy update: An introduction to the pharmacology, safety, and efficacy of bispecific antibodies in relapsed or refractory multiple myeloma"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-3651","authenticated-orcid":false,"given":"Dawud","family":"Ellayan","sequence":"first","affiliation":[{"name":"Banner University of Arizona Cancer Center , Tucson, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"9","key":"2026072012483370700_zxag203-B1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2026072012483370700_zxag203-B2","doi-asserted-by":"publisher","first-page":"e70145","DOI":"10.1002\/jha2.70145","article-title":"Real-world treatment patterns and clinical outcomes among patients with triple-class\u2013exposed and BCMA-exposed multiple myeloma within the United States","volume":"6","author":"Mian","year":"2025","journal-title":"EJHaem"},{"key":"2026072012483370700_zxag203-B3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"2026072012483370700_zxag203-B4","doi-asserted-by":"publisher","first-page":"1304365","DOI":"10.3389\/fimmu.2023.1304365","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"2026072012483370700_zxag203-B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"issue":"2","key":"2026072012483370700_zxag203-B6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"issue":"10","key":"2026072012483370700_zxag203-B7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"2026072012483370700_zxag203-B8","doi-asserted-by":"publisher","first-page":"e473148","DOI":"10.1200\/EDBK-25-473148","article-title":"Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances","volume":"45","author":"Guidi","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026072012483370700_zxag203-B9","author":"Food and Drug Administration"},{"key":"2026072012483370700_zxag203-B10","author":"Food and Drug Administration"},{"key":"2026072012483370700_zxag203-B11","author":"Food and Drug Administration"},{"key":"2026072012483370700_zxag203-B12","author":"Food and Drug Administration"},{"issue":"1","key":"2026072012483370700_zxag203-B13","doi-asserted-by":"publisher","first-page":"e35665","DOI":"10.1002\/cncr.35665","article-title":"Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1","volume":"131","author":"Cai","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"2026072012483370700_zxag203-B14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11523-025-01149-1","article-title":"Teclistamab dosing in responders: modeling and simulation results from the MajesTEC-1 study in relapsed\/refractory multiple myeloma","volume":"20","author":"Guo","year":"2025","journal-title":"Target Oncol"},{"key":"2026072012483370700_zxag203-B15","volume-title":"Package insert","author":"Tecvayli (teclistamab-cqyv)","year":"2022"},{"key":"2026072012483370700_zxag203-B16","volume-title":"Package insert","author":"Elrexfio (elranatamab-bcmm)","year":"2023"},{"key":"2026072012483370700_zxag203-B17","author":"Lynozyfic","year":"2025"},{"key":"2026072012483370700_zxag203-B18","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2024-206912","article-title":"A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Mian","year":"2024","journal-title":"Blood"},{"issue":"16 suppl","key":"2026072012483370700_zxag203-B19","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1200\/JCO.2025.43.16_suppl.7527","article-title":"Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"43","author":"Baljevic","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072012483370700_zxag203-B20","volume-title":"Package insert","author":"Talvey (talquetamab-tgvs)","year":"2023"},{"key":"2026072012483370700_zxag203-B21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood-2025-700","article-title":"Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in relapsed\/refractory multiple myeloma (RRMM): first results from the phase Ib CAMMA 3 study","volume":"146","author":"Ho","year":"2025","journal-title":"Blood"},{"issue":"31","key":"2026072012483370700_zxag203-B22","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026072012483370700_zxag203-B23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2026072012483370700_zxag203-B24","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2026072012483370700_zxag203-B25","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"2026072012483370700_zxag203-B26","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026072012483370700_zxag203-B27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol"},{"issue":"23","key":"2026072012483370700_zxag203-B28","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5D\u00d7CD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026072012483370700_zxag203-B30","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026072012483370700_zxag203-B31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11523-025-01134-8","article-title":"Dose optimization of elranatamab to mitigate the risk of cytokine release syndrome in patients with multiple myeloma","volume":"20","author":"Elmeliegy","year":"2025","journal-title":"Target Oncol"},{"issue":"10","key":"2026072012483370700_zxag203-B32","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2026072012483370700_zxag203-B33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jjco\/hyae068","article-title":"Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3","volume":"54","author":"Iida","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026072012483370700_zxag203-B34","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2024-199542","article-title":"Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026072012483370700_zxag203-B35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026072012483370700_zxag203-B36","doi-asserted-by":"publisher","first-page":"103877","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J Pharm Sci"},{"issue":"10 suppl","key":"2026072012483370700_zxag203-B37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/OP.2025.21.10_suppl.379","article-title":"Real-world evidence: patient preference of intravenous (IV) vs. subcutaneous (SQ) administration of oncology medications","volume":"21","author":"Ogle","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"2026072012483370700_zxag203-B38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/antib11030056","article-title":"Alternative routes of administration for therapeutic antibodies\u2014state of the art","volume":"11","author":"Pitiot","year":"2022","journal-title":"Antibodies"},{"key":"2026072012483370700_zxag203-B39","doi-asserted-by":"publisher","first-page":"102974","DOI":"10.1016\/j.ctrv.2025.102974","article-title":"Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: a clinical, economic and patient perspective","volume":"139","author":"George","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2026072012483370700_zxag203-B40","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1080\/13696998.2025.2555141","article-title":"Comparison of utilization and total Medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies","volume":"28","author":"Kardel","year":"2025","journal-title":"J Med Econ"},{"issue":"16 suppl","key":"2026072012483370700_zxag203-B41","doi-asserted-by":"publisher","first-page":"e23163","DOI":"10.1200\/JCO.2025.43.16_suppl.e23163","article-title":"The cost of convenience: evaluating economic differences in SQ and IV biotherapeutic formulations","volume":"43","author":"Indurlal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026072012483370700_zxag203-B42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12185-024-03884-z","article-title":"A phase 1\/2 study of teclistamab, a humanized BCMA","volume":"121","author":"Ishida","year":"2025","journal-title":"Int J Hematol"},{"key":"2026072012483370700_zxag203-B43","doi-asserted-by":"publisher","first-page":"1630146","DOI":"10.3389\/fonc.2025.1630146","article-title":"A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma","volume":"15","author":"Garfall","year":"2025","journal-title":"Front Oncol"},{"issue":"19","key":"2026072012483370700_zxag203-B44","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","article-title":"Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies","volume":"9","author":"Kowalski","year":"2025","journal-title":"Blood Adv"},{"key":"2026072012483370700_zxag203-B45","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/S2152-2650(24)01667-7","article-title":"MM-344 longer-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"van de Donk","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B46","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/blood-2023-189878","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab administration","volume":"142","author":"Marin","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026072012483370700_zxag203-B47","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"HemaSphere"},{"issue":"16 suppl","key":"2026072012483370700_zxag203-B48","doi-asserted-by":"publisher","first-page":"e19504","DOI":"10.1200\/JCO.2025.43.16_suppl.e19504","article-title":"Tocilizumab prophylaxis for outpatient administration of teclistamab in relapsed\/refractory multiple myeloma","volume":"43","author":"Jadot","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026072012483370700_zxag203-B49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"S3","key":"2026072012483370700_zxag203-B50","doi-asserted-by":"publisher","first-page":"e43149cb","DOI":"10.1097\/01.HS9.0000970548.43149.cb","article-title":"P911: evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1","volume":"7","author":"van de Donk","year":"2023","journal-title":"HemaSphere"},{"key":"2026072012483370700_zxag203-B51","doi-asserted-by":"publisher","first-page":"S908","DOI":"10.1016\/S2152-2650(25)02580-7","article-title":"MM-216: prophylactic tocilizumab to mitigate cytokine release syndrome and outpatient dosing of talquetamab in relapsed\/refractory multiple myeloma: updated phase 1\/2 MonumenTAL-1 results","volume":"25","author":"Schinke","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026072012483370700_zxag203-B52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma","volume":"19","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"2026072012483370700_zxag203-B53","author":"National Comprehensive Cancer Network"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B54","doi-asserted-by":"publisher","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026072012483370700_zxag203-B55","doi-asserted-by":"publisher","first-page":"e433516","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific antibody use in patients with lymphoma and multiple myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026072012483370700_zxag203-B56","doi-asserted-by":"publisher","first-page":"1721820","DOI":"10.3389\/fimmu.2026.1721820","article-title":"Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience","volume":"17","author":"Marneni","year":"2026","journal-title":"Front Immunol"},{"issue":"1","key":"2026072012483370700_zxag203-B57","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"2026072012483370700_zxag203-B58","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2024015477","article-title":"Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma","volume":"9","author":"O\u2019Donnell","year":"2025","journal-title":"Blood Adv"},{"key":"2026072012483370700_zxag203-B59","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood.V130.Suppl_1.2755.2755","article-title":"B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies","volume":"130","author":"Khattar","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026072012483370700_zxag203-B60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"20","key":"2026072012483370700_zxag203-B61","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2026072012483370700_zxag203-B62","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1615\/critrevimmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"6","key":"2026072012483370700_zxag203-B63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026072012483370700_zxag203-B64","author":"Food and Drug Administration"},{"key":"2026072012483370700_zxag203-B65","author":"Food and Drug Administration"},{"key":"2026072012483370700_zxag203-B66","author":"Food and Drug Administration"},{"issue":"25","key":"2026072012483370700_zxag203-B67","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B68","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1182\/blood-2023-188080","article-title":"The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B69","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1182\/blood-2024-199733","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up and selected high-risk subgroup analyses of the Linker-MM1 study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026072012483370700_zxag203-B70","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11523-025-01168-y","article-title":"Population exposure\u2014response efficacy analysis of elranatamab (PF-06863135) in patients with multiple myeloma","volume":"20","author":"Lon","year":"2025","journal-title":"Target Oncol"},{"issue":"8","key":"2026072012483370700_zxag203-B71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026072012483370700_zxag203-B72","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"18","key":"2026072012483370700_zxag203-B73","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell\u2013redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"2026072012483370700_zxag203-B74","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA approval summary: teclistamab\u2014a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026072012483370700_zxag203-B75","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure\u2013response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"issue":"5","key":"2026072012483370700_zxag203-B76","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","article-title":"Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma","volume":"40","author":"Moreau","year":"2023","journal-title":"Adv Ther"},{"issue":"5","key":"2026072012483370700_zxag203-B77","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","article-title":"Comparative efficacy of teclistamab versus physician\u2019s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma","volume":"23","author":"Mateos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026072012483370700_zxag203-B78","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026072012483370700_zxag203-B79","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2023.2236303","article-title":"Elranatamab: a new promising BispAb in multiple myeloma treatment","volume":"23","author":"Grosicki","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026072012483370700_zxag203-B80","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2026072012483370700_zxag203-B81","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2023-0995","article-title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","volume":"20","author":"Costa","year":"2024","journal-title":"Future Oncol"},{"issue":"5","key":"2026072012483370700_zxag203-B82","doi-asserted-by":"publisher","first-page":"e240236","DOI":"10.57264\/cer-2024-0236","article-title":"Elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma: an updated matching-adjusted indirect comparison","volume":"14","author":"Mol","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"5","key":"2026072012483370700_zxag203-B83","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/bjh.19346","article-title":"Impact of elranatamab on quality of life: patient-reported outcomes from MagnetisMM-3","volume":"204","author":"Mohty","year":"2024","journal-title":"Br J Haematol"},{"key":"2026072012483370700_zxag203-B84","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/CEOR.S501404","article-title":"Economic impact of elranatamab for treatment of patients with relapsed or refractory multiple myeloma","volume":"17","author":"Shah","year":"2025","journal-title":"Clin Outcomes Res"},{"issue":"2","key":"2026072012483370700_zxag203-B85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40487-025-00333-7","article-title":"Cost-effectiveness of elranatamab versus current therapies for the management of patients with triple-class exposed, relapsed and refractory multiple myeloma, including other bispecific and physician\u2019s choice of treatment in Spain","volume":"13","author":"Encinas","year":"2025","journal-title":"Oncol Ther"},{"issue":"1","key":"2026072012483370700_zxag203-B86","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/13696998.2025.2514909","article-title":"Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States","volume":"28","author":"Gordan","year":"2025","journal-title":"J Med Econ"},{"issue":"1","key":"2026072012483370700_zxag203-B87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jha2.69","article-title":"Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed\/refractory multiple myeloma","volume":"1","author":"Foureau","year":"2020","journal-title":"EJHaem"},{"issue":"16 suppl","key":"2026072012483370700_zxag203-B88","doi-asserted-by":"publisher","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","article-title":"Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Rodriguez Valdes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B89","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1182\/blood-2023-180127","article-title":"Pharmacokinetics and immunogenicity of Abbv-383, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific T-cell-redirecting antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Polepally","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026072012483370700_zxag203-B90","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"issue":"1","key":"2026072012483370700_zxag203-B91","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematology"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B92","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1182\/blood-2024-200679","article-title":"Comparative effectiveness of linvoseltamab versus current real-world (RW) standard-of-care (SOC) therapies in triple-class exposed relapsed\/refractory multiple myeloma (RRMM): key subgroups analysis","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026072012483370700_zxag203-B93","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2025.06.014","article-title":"Indirect comparison of linvoseltamab versus teclistamab for the treatment of triple-class exposed relapsed\/refractory multiple myeloma","volume":"25","author":"Lee","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B94","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2023-179170","article-title":"Health-related quality of life (HRQoL) among patients with triple-class exposed relapsed\/refractory multiple myeloma (RRMM) treated with linvoseltamab in Linker-MM1: interim assessment up to 36 weeks of treatment","volume":"142","author":"Hoffman","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026072012483370700_zxag203-B95","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/bjh.70116","article-title":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: advances, resistance and combination strategies","volume":"207","author":"Wang","year":"2025","journal-title":"Br J Haematol"},{"key":"2026072012483370700_zxag203-B96","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/S2152-2650(21)02229-1","article-title":"P-095: normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues","volume":"21","author":"Goldsmith","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2026072012483370700_zxag203-B97","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell\u2013redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2026072012483370700_zxag203-B98","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2026072012483370700_zxag203-B99","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0167-4781(01)00197-x","article-title":"Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D1","volume":"1518","author":"Br\u00e4uner-Osborne","year":"2001","journal-title":"Biochim Biophys Acta Gene Struct Expr"},{"issue":"9","key":"2026072012483370700_zxag203-B100","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"2026072012483370700_zxag203-B101","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5D\u00d7CD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2026072012483370700_zxag203-B102","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D \u00d7 CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026072012483370700_zxag203-B103","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.70004","article-title":"Recommended phase II doses of talquetamab in patients with relapsed\/refractory multiple myeloma from MonumenTAL-1: clinical pharmacology results","volume":"118","author":"Gong","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"2026072012483370700_zxag203-B104","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1080\/14796694.2025.2555170","article-title":"Managing side effects of talquetamab for relapsed\/refractory multiple myeloma in MonumenTAL-1: a plain language summary","volume":"21","author":"Chari","year":"2025","journal-title":"Future Oncol"},{"issue":"14","key":"2026072012483370700_zxag203-B105","doi-asserted-by":"publisher","first-page":"e35927","DOI":"10.1002\/cncr.35927","article-title":"Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"131","author":"Schinke","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"2026072012483370700_zxag203-B106","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026072012483370700_zxag203-B107","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"issue":"10","key":"2026072012483370700_zxag203-B108","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody\u2013drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2026072012483370700_zxag203-B109","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"issue":"1","key":"2026072012483370700_zxag203-B110","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2026072012483370700_zxag203-B111","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.leu.2404445","article-title":"Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma","volume":"21","author":"Ise","year":"2007","journal-title":"Leukemia"},{"issue":"16 suppl","key":"2026072012483370700_zxag203-B112","doi-asserted-by":"publisher","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B113","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"17","key":"2026072012483370700_zxag203-B114","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/cancers17172727","article-title":"Safety and efficacy of bispecific antibody treatment in relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of proportions from clinical trials","volume":"17","author":"Bakogeorgou","year":"2025","journal-title":"Cancers"},{"key":"2026072012483370700_zxag203-B115","doi-asserted-by":"publisher","first-page":"1348955","DOI":"10.3389\/fimmu.2024.1348955","article-title":"Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"2026072012483370700_zxag203-B116","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1182\/blood-2023-177669","article-title":"Co-expression of GPRC5D, FcRH5 and BCMA suggests that targeting more than one cell surface marker may be a viable strategy in relapsed\/refractory multiple myeloma (RRMM): biomarker results from the phase I study of forimtamig, a GPRC5D\u00d7CD3 bispecific antibody","volume":"142","author":"Dekhtiarenko","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026072012483370700_zxag203-B117","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026072012483370700_zxag203-B118","author":"Janssen Research & Development"},{"issue":"suppl 2","key":"2026072012483370700_zxag203-B119","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2025-LBA-6","article-title":"Phase 3 randomized study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd\/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): results of MajesTEC-3","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"key":"2026072012483370700_zxag203-B120","author":"European Myeloma Network"},{"key":"2026072012483370700_zxag203-B121","author":"Janssen Research & Development"},{"key":"2026072012483370700_zxag203-B122","author":"Memorial Sloan Kettering Cancer Center"},{"key":"2026072012483370700_zxag203-B123","author":"Janssen Research & Development"},{"key":"2026072012483370700_zxag203-B124","author":"Pfizer"},{"key":"2026072012483370700_zxag203-B125","author":"Pfizer"},{"key":"2026072012483370700_zxag203-B126","author":"Pfizer"},{"key":"2026072012483370700_zxag203-B127","author":"Pfizer"},{"key":"2026072012483370700_zxag203-B128","author":"Regeneron Pharmaceuticals"},{"key":"2026072012483370700_zxag203-B129","author":"Regeneron Pharmaceuticals"},{"key":"2026072012483370700_zxag203-B130","author":"Regeneron Pharmaceuticals"},{"key":"2026072012483370700_zxag203-B131","author":"Regeneron Pharmaceuticals"},{"key":"2026072012483370700_zxag203-B132","author":"AbbVie"},{"key":"2026072012483370700_zxag203-B133","author":"Genentech"},{"key":"2026072012483370700_zxag203-B134","author":"Roche"},{"issue":"suppl 1","key":"2026072012483370700_zxag203-B135","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1182\/blood-2025-2282","article-title":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in combination with pomalidomide in patients with relapsed\/refractory multiple myeloma: updated safety and efficacy results from the phase 1b MonumenTAL-2 study","volume":"146","author":"Quach","year":"2025","journal-title":"Blood"},{"key":"2026072012483370700_zxag203-B136","author":"Janssen Research & Development"},{"key":"2026072012483370700_zxag203-B137","author":"Janssen Research & Development"},{"key":"2026072012483370700_zxag203-B138","author":"Janssen Research & Development"},{"key":"2026072012483370700_zxag203-B139","author":"Janssen Research & Development"},{"issue":"8","key":"2026072012483370700_zxag203-B140","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"16 suppl","key":"2026072012483370700_zxag203-B141","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results","volume":"43","author":"van de Donk","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072012483370700_zxag203-B142","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1182\/blood-2023-187106","article-title":"A phase 1, first-in-human, dose escalation and dose-expansion study of a BCMAxCD38\u00d7CD3 targeting trispecific antibody ISB 2001 in subjects with relapsed\/refractory multiple myeloma","volume":"142","author":"Sia","year":"2023","journal-title":"Blood"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag203\/68755456\/zxag203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag203\/68755456\/zxag203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:48:42Z","timestamp":1784566122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag203\/8732017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":142,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag203","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"zxag203"}}